These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 33841329)

  • 1. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
    Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
    J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Renin Activity to Guide Mineralocorticoid Receptor Antagonist Therapy in Patients with Low Renin and Hypertension.
    Mansur A; Vaidya A; Turchin A
    Am J Hypertens; 2023 Jul; 36(8):455-461. PubMed ID: 37013957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
    Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
    J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtype Identification of Surgically Curable Primary Aldosteronism During Treatment With Mineralocorticoid Receptor Blockade.
    Pintus G; Seccia TM; Amar L; Azizi M; Riester A; Reincke M; Widimský J; Naruse M; Kocjan T; Negro A; Kline G; Tanabe A; Satoh F; Rump LC; Vonend O; Fuller PJ; Yang J; Chee NYN; Magill SB; Shafigullina Z; Quinkler M; Oliveras A; Lee BC; Chang CC; Wu VC; Krátká Z; Battistel M; Bagordo D; Caroccia B; Ceolotto G; Rossitto G; Rossi GP
    Hypertension; 2024 Jun; 81(6):1391-1399. PubMed ID: 38525605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism.
    Nanba AT; Wannachalee T; Shields JJ; Byrd JB; Rainey WE; Auchus RJ; Turcu AF
    J Clin Endocrinol Metab; 2019 Feb; 104(2):487-492. PubMed ID: 30239792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
    Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
    High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of left ventricular hypertrophy in patients with primary aldosteronism/low-renin hypertension on low-dose spironolactone.
    Ori Y; Chagnac A; Korzets A; Zingerman B; Herman-Edelstein M; Bergman M; Gafter U; Salman H
    Nephrol Dial Transplant; 2013 Jul; 28(7):1787-93. PubMed ID: 23378418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Patient with Bilateral Primary Aldosteronism Refractory to Oral Eplerenone Who Responded to Esaxerenone with Increased Renin Activity.
    Okamura K; Matsushima M; Yamamoto F; Takamiya Y; Okuda T; Shirai K; Okamura K; Urata H
    Am J Case Rep; 2020 Jan; 21():e920615. PubMed ID: 31907345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
    Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
    Riester A; Reincke M
    Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of mineralocorticoid and AT-1 receptor antagonism on the aldosterone-renin ratio (ARR) in primary aldosteronism patients (EMIRA Study): rationale and design.
    Rossitto G; Cesari M; Ceolotto G; Maiolino G; Seccia TM; Rossi GP
    J Hum Hypertens; 2019 Feb; 33(2):167-171. PubMed ID: 30518805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.
    Hundemer GL; Curhan GC; Yozamp N; Wang M; Vaidya A
    JAMA Cardiol; 2018 Aug; 3(8):768-774. PubMed ID: 30027227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary aldosteronism in hypertensive patients: clinical implications and target therapy.
    Papanastasiou L; Markou A; Pappa T; Gouli A; Tsounas P; Fountoulakis S; Kounadi T; Tsiama V; Dasou A; Gryparis A; Samara C; Zografos G; Kaltsas G; Chrousos G; Piaditis G
    Eur J Clin Invest; 2014 Aug; 44(8):697-706. PubMed ID: 24909545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Reversal of Renin Suppression With Long-Term Renal Outcome in Medically Treated Primary Aldosteronism.
    Katsuragawa S; Goto A; Shinoda S; Inoue K; Nakai K; Saito J; Nishikawa T; Tsurutani Y
    Hypertension; 2023 Sep; 80(9):1909-1920. PubMed ID: 37449450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism.
    Katabami T; Fukuda H; Tsukiyama H; Tanaka Y; Takeda Y; Kurihara I; Ito H; Tsuiki M; Ichijo T; Wada N; Shibayama Y; Yoshimoto T; Ogawa Y; Kawashima J; Sone M; Inagaki N; Takahashi K; Fujita M; Watanabe M; Matsuda Y; Kobayashi H; Shibata H; Kamemura K; Otsuki M; Fujii Y; Yamamoto K; Ogo A; Yanase T; Suzuki T; Naruse M;
    J Hypertens; 2019 Jul; 37(7):1513-1520. PubMed ID: 31145370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism.
    Seifarth C; Trenkel S; Schobel H; Hahn EG; Hensen J
    Clin Endocrinol (Oxf); 2002 Oct; 57(4):457-65. PubMed ID: 12354127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unadjusted Plasma Renin Activity as a "First-Look" Test to Decide Upon Further Investigations for Primary Aldosteronism.
    Rye P; Chin A; Pasieka J; So B; Harvey A; Kline G
    J Clin Hypertens (Greenwich); 2015 Jul; 17(7):541-6. PubMed ID: 25756935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.